ImmunityBio (IBRX) Competitors $2.31 +0.07 (+3.13%) Closing price 04:00 PM EasternExtended Trading$2.33 +0.02 (+0.69%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX vs. BBIO, VRNA, ELAN, BPMC, ROIV, GRFS, LEGN, RVMD, RYTM, and RNAShould you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. ImmunityBio vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences BridgeBio Pharma (NASDAQ:BBIO) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Does the media refer more to BBIO or IBRX? In the previous week, BridgeBio Pharma had 9 more articles in the media than ImmunityBio. MarketBeat recorded 15 mentions for BridgeBio Pharma and 6 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.73 beat BridgeBio Pharma's score of 0.72 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, BBIO or IBRX? BridgeBio Pharma has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Which has better valuation & earnings, BBIO or IBRX? ImmunityBio has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$221.90M42.28-$535.76M-$4.09-12.00ImmunityBio$14.74M148.14-$413.56M-$0.48-4.81 Is BBIO or IBRX more profitable? BridgeBio Pharma has a net margin of -329.25% compared to ImmunityBio's net margin of -648.57%. Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-329.25% N/A -85.69% ImmunityBio -648.57%N/A -113.86% Do insiders & institutionals have more ownership in BBIO or IBRX? 99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 76.8% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend BBIO or IBRX? BridgeBio Pharma currently has a consensus target price of $61.35, suggesting a potential upside of 25.01%. ImmunityBio has a consensus target price of $10.75, suggesting a potential upside of 365.37%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryImmunityBio beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks. Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBRX vs. The Competition Export to ExcelMetricImmunityBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.18B$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-4.8121.1431.1525.97Price / Sales148.14399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book-3.858.079.116.39Net Income-$413.56M-$54.72M$3.26B$265.66M7 Day Performance-9.41%2.62%2.11%1.98%1 Month Performance-14.76%7.63%5.12%1.33%1 Year Performance-44.47%13.11%31.25%21.15% ImmunityBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBRXImmunityBio2.5712 of 5 stars$2.31+3.1%$10.75+365.4%-49.1%$2.18B$14.74M-4.81590BBIOBridgeBio Pharma4.7461 of 5 stars$49.72+1.3%$61.35+23.4%+96.5%$9.46B$221.90M-12.10400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.4678 of 5 stars$105.25+0.1%$109.00+3.6%+276.7%$8.96B$42.28M-106.3130Positive NewsShort Interest ↓ELANElanco Animal Health3.1498 of 5 stars$17.70+1.5%$17.33-2.0%+17.8%$8.80B$4.44B20.599,000Positive NewsAnalyst DowngradeBPMCBlueprint Medicines0.5049 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.4873 of 5 stars$11.75+1.5%$16.50+40.5%+0.2%$7.98B$29.05M-16.78860GRFSGrifols3.721 of 5 stars$10.59-0.1%$10.30-2.7%+31.4%$7.30B$7.81B9.0723,822Short Interest ↑LEGNLegend Biotech3.7026 of 5 stars$37.16+0.5%$72.38+94.8%-37.1%$6.82B$627.24M-42.172,609RVMDRevolution Medicines4.4199 of 5 stars$35.63+1.0%$68.82+93.1%-19.4%$6.68B$11.58M-7.94250Positive NewsAnalyst RevisionRYTMRhythm Pharmaceuticals3.8106 of 5 stars$96.90+0.5%$101.57+4.8%+124.1%$6.43B$156.29M-32.17140News CoveragePositive NewsRNAAvidity Biosciences3.2165 of 5 stars$46.07-0.4%$67.00+45.4%-0.8%$5.95B$10.90M-15.43190Positive NewsOptions Volume Related Companies and Tools Related Companies BBIO Alternatives VRNA Alternatives ELAN Alternatives BPMC Alternatives ROIV Alternatives GRFS Alternatives LEGN Alternatives RVMD Alternatives RYTM Alternatives RNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IBRX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access